Sandra’s Day by Ramesh

HEALTH-CARE SYMPOSIUM

aged care) claims that the “pharmaceutical industry is not particularly innovative and it is growing less so each year.” Just the opposite is true. The total number of drugs and biotech products getting orphan-drug (i.e., drugs for rare diseases), fast-track, priority, or accelerated-approval status has increased more than four-fold, from approximately 120 drugs in such categories in 1995 to about 500 in 2002.